{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T17:24:45Z","timestamp":1783790685661,"version":"3.55.0"},"reference-count":58,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"vor","delay-in-days":1096,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jpsmjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pain and Symptom Management"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.jpainsymman.2019.02.006","type":"journal-article","created":{"date-parts":[[2019,2,15]],"date-time":"2019-02-15T21:47:15Z","timestamp":1550267235000},"page":"989-998.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Clinically Significant Drug-Drug Interactions Involving Medications Used for Symptom Control in Patients With Advanced Malignant Disease: A Systematic Review"],"prefix":"10.1016","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3329-5402","authenticated-orcid":false,"given":"Aleksandra","family":"Kotlinska-Lemieszek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e5l","family":"Klepstad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dagny Faksv\u00e5g","family":"Haugen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpainsymman.2019.02.006_bib1","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/j.1532-5415.2007.01124.x","article-title":"Prescribing in palliative care as death approaches","volume":"55","author":"Currow","year":"2007","journal-title":"J\u00a0Am Geriatr Soc"},{"key":"10.1016\/j.jpainsymman.2019.02.006_bib2","first-page":"427","article-title":"Changes in medication profile among patients with advanced cancer admitted to an acute palliative care unit","volume":"23","author":"Hui","year":"2015","journal-title":"Support Care Cancer Off J Multinatl Assoc Support Care Cancer"},{"key":"10.1016\/j.jpainsymman.2019.02.006_bib3","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.jpainsymman.2014.03.008","article-title":"Polypharmacy in patients with advanced cancer and pain: a European cross-sectional study of 2282 patients","volume":"48","author":"Kotlinska-Lemieszek","year":"2014","journal-title":"J\u00a0Pain Symptom Manage"},{"key":"10.1016\/j.jpainsymman.2019.02.006_bib4","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1002\/cncr.24942","article-title":"Antineoplastic therapy use in patients with advanced cancer admitted to an acute palliative care unit at a comprehensive cancer center: a simultaneous care model","volume":"116","author":"Hui","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.jpainsymman.2019.02.006_bib5","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/clpt.2011.258","article-title":"High-risk prescribing and incidence of frailty among older community-dwelling men","volume":"91","author":"Gnjidic","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jpainsymman.2019.02.006_bib6","doi-asserted-by":"crossref","first-page":"e333","DOI":"10.1016\/S1470-2045(15)00080-7","article-title":"Polypharmacy in patients with advanced cancer and the role of medication discontinuation","volume":"16","author":"LeBlanc","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jpainsymman.2019.02.006_bib7","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jpainsymman.2007.06.009","article-title":"Potential drug interactions in cancer patients receiving supportive care exclusively","volume":"35","author":"Riechelmann","year":"2008","journal-title":"J\u00a0Pain Symptom Manage"},{"key":"10.1016\/j.jpainsymman.2019.02.006_bib8","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1007\/s00280-004-0998-4","article-title":"Potential for drug interactions in hospitalized cancer patients","volume":"56","author":"Riechelmann","year":"2005","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.jpainsymman.2019.02.006_bib9","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1093\/jnci\/djk130","article-title":"Potential drug interactions and duplicate prescriptions among cancer patients","volume":"99","author":"Riechelmann","year":"2007","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.jpainsymman.2019.02.006_bib10","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1093\/annonc\/mdp369","article-title":"Drug interactions in oncology: how common are they?","volume":"20","author":"Riechelmann","year":"2009","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.jpainsymman.2019.02.006_bib11","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1177\/0269216311412231","article-title":"Drug interactions in palliative care\u2013it's more than cytochrome P450","volume":"26","author":"Gaertner","year":"2012","journal-title":"Palliat Med"},{"key":"10.1016\/j.jpainsymman.2019.02.006_bib12","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/BF03261971","article-title":"Drug interactions in dying patients: a retrospective analysis of hospice inpatients in Germany","volume":"35","author":"Frechen","year":"2012","journal-title":"Drug Saf"},{"key":"10.1016\/j.jpainsymman.2019.02.006_bib13","doi-asserted-by":"crossref","first-page":"5255","DOI":"10.2147\/DDDT.S86983","article-title":"Clinically significant drug-drug interactions involving opioid analgesics used for pain treatment in patients with cancer: a systematic review","volume":"9","author":"Kotlinska-Lemieszek","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.jpainsymman.2019.02.006_bib15","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1345\/aph.1L528","article-title":"Fatal liver failure in a patient on acetaminophen treated with sunitinib malate and levothyroxine","volume":"43","author":"Weise","year":"2009","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jpainsymman.2019.02.006_bib16","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1016\/S0140-6736(86)91706-X","article-title":"Acute renal failure due to concomitant action of methotrexate and indomethacin","volume":"1","author":"Maiche","year":"1986","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.jpainsymman.2019.02.006_bib17","first-page":"342","article-title":"Acute renal failure and death following sequential intermediate-dose methotrexate and 5-FU: a possible adverse effect due to concomitant indomethacin administration","volume":"69","author":"Ellison","year":"1985","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/j.jpainsymman.2019.02.006_bib18","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1136\/pgmj.65.770.950","article-title":"Life-threatening acute hyponatraemia induced by low dose cyclophosphamide and indomethacin","volume":"65","author":"Webberley","year":"1989","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.jpainsymman.2019.02.006_bib19","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1345\/aph.1A354","article-title":"Probable metabolic interaction of doxifluridine with phenytoin","volume":"36","author":"Konishi","year":"2002","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jpainsymman.2019.02.006_bib20","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/sj.bjc.6601137","article-title":"Phenytoin toxicity due to fluoropyrimidines (5FU\/capecitabine): three case reports","volume":"89","author":"Brickell","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jpainsymman.2019.02.006_bib21","doi-asserted-by":"crossref","first-page":"264","DOI":"10.3747\/co.v18i6.839","article-title":"Phenytoin toxicity in a patient receiving 5-fluorouracil-based chemotherapy for metastatic colorectal cancer","volume":"18","author":"Kuruvilla","year":"2011","journal-title":"Curr Oncol Tor Ont"},{"key":"10.1016\/j.jpainsymman.2019.02.006_bib22","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1097\/CAD.0b013e32834a6c69","article-title":"Capecitabine-phenytoin interaction is dose dependent with an unexpected time course","volume":"22","author":"Privitera","year":"2011","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.jpainsymman.2019.02.006_bib23","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1097\/MJT.0b013e318293b10a","article-title":"Combination of capecitabine and phenytoin may cause phenytoin intoxication: a case report","volume":"22","author":"Ciftci","year":"2015","journal-title":"Am J Ther"},{"key":"10.1016\/j.jpainsymman.2019.02.006_bib24","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1176\/appi.psy.48.4.359","article-title":"Delirium likely caused by interaction between phenytoin and temozolomide","volume":"48","author":"Levy","year":"2007","journal-title":"Psychosomatics"},{"key":"10.1016\/j.jpainsymman.2019.02.006_bib25","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.lungcan.2007.02.011","article-title":"Significant drug interaction: phenytoin toxicity due to erlotinib","volume":"57","author":"Grenader","year":"2007","journal-title":"Lung Cancer Amst Neth"},{"key":"10.1016\/j.jpainsymman.2019.02.006_bib26","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.lungcan.2016.08.009","article-title":"Drug interaction between erlotinib and phenytoin for brain metastases in a patient with nonsmall cell lung cancer","volume":"101","author":"Ohgami","year":"2016","journal-title":"Lung Cancer Amst Neth"},{"key":"10.1016\/j.jpainsymman.2019.02.006_bib27","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/j.1528-1157.1995.tb00494.x","article-title":"High-dose tamoxifen in treatment of brain tumors: interaction with antiepileptic drugs","volume":"36","author":"Rabinowicz","year":"1995","journal-title":"Epilepsia"},{"key":"10.1016\/j.jpainsymman.2019.02.006_bib28","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/clpt.1988.45","article-title":"An interaction between cytostatic and anticonvulsant drugs","volume":"43","author":"Neef","year":"1988","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jpainsymman.2019.02.006_bib29","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/0002-9343(90)90308-Z","article-title":"Decreased phenytoin level after carboplatin treatment","volume":"89","author":"Dofferhoff","year":"1990","journal-title":"Am J Med"},{"key":"10.1016\/j.jpainsymman.2019.02.006_bib30","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1528-1157.1983.tb04868.x","article-title":"Decreased phenytoin level during antineoplastic therapy: a case report","volume":"24","author":"Bollini","year":"1983","journal-title":"Epilepsia"},{"key":"10.1016\/j.jpainsymman.2019.02.006_bib31","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/sj.bjc.6601607","article-title":"Oral tegafur\/folinic acid chemotherapy decreases phenytoin efficacy","volume":"90","author":"Veldhorst-Janssen","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jpainsymman.2019.02.006_bib32","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1177\/106002809603000516","article-title":"Possible interaction involving phenytoin, dexamethasone, and antineoplastic agents: a case report and review","volume":"30","author":"Gattis","year":"1996","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jpainsymman.2019.02.006_bib33","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/S0140-6736(78)90938-8","article-title":"Phenytoin\/dexamethasone interaction: a clinical problem","volume":"1","author":"McLelland","year":"1978","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.jpainsymman.2019.02.006_bib34","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1177\/106002809502900918","article-title":"Effect of dexamethasone on the decrease of serum phenytoin concentrations","volume":"29","author":"Recuenco","year":"1995","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jpainsymman.2019.02.006_bib35","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1365-2796.1993.tb00710.x","article-title":"Thrombocytopenia following administration of phenytoin, dexamethasone and cimetidine: a case report and a potential mechanism","volume":"234","author":"Arbiser","year":"1993","journal-title":"J\u00a0Intern Med"},{"key":"10.1016\/j.jpainsymman.2019.02.006_bib36","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.jpainsymman.2010.11.014","article-title":"Adverse drug reactions and drug interactions as causes of hospital admission in oncology","volume":"42","author":"Miranda","year":"2011","journal-title":"J\u00a0Pain Symptom Manage"},{"key":"10.1016\/j.jpainsymman.2019.02.006_bib37","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1002\/j.1875-9114.1998.tb03868.x","article-title":"Fatal toxic epidermal necrolysis related to lamotrigine administration","volume":"18","author":"Page","year":"1998","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jpainsymman.2019.02.006_bib38","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/0090-3019(89)90203-6","article-title":"Catastrophic neurologic signs due to drug interaction: Tegretol and Darvon","volume":"32","author":"Oles","year":"1989","journal-title":"Surg Neurol"},{"key":"10.1016\/j.jpainsymman.2019.02.006_bib39","doi-asserted-by":"crossref","first-page":"907","DOI":"10.7326\/0003-4819-118-11-199306010-00021","article-title":"Drug interaction of terfenadine and carbamazepine","volume":"118","author":"Hirschfeld","year":"1993","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jpainsymman.2019.02.006_bib40","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jpainsymman.2006.02.006","article-title":"Methadone-induced respiratory depression after discontinuing carbamazepine administration","volume":"32","author":"Ben\u00edtez-Rosario","year":"2006","journal-title":"J\u00a0Pain Symptom Manage"},{"key":"10.1016\/j.jpainsymman.2019.02.006_bib41","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1177\/1049909108319260","article-title":"Oral morphine overdose in a cancer patient antagonized by prolonged naloxone infusion","volume":"25","author":"Upadhyay","year":"2008","journal-title":"Am J Hosp Palliat Care"},{"key":"10.1016\/j.jpainsymman.2019.02.006_bib42","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/BF03016672","article-title":"Serotonin toxicity caused by an interaction between fentanyl and paroxetine","volume":"55","author":"Rang","year":"2008","journal-title":"Can J Anaesth J Can Anesth"},{"key":"10.1016\/j.jpainsymman.2019.02.006_bib43","first-page":"261787","article-title":"An unusual case of serotonin syndrome with oxycodone and citalopram","volume":"2012","author":"Walter","year":"2012","journal-title":"Case Rep Oncol Med"},{"key":"10.1016\/j.jpainsymman.2019.02.006_bib44","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1345\/aph.1E523","article-title":"Serotonin toxicity associated with concomitant use of linezolid","volume":"39","author":"Bergeron","year":"2005","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jpainsymman.2019.02.006_bib45","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.genhosppsych.2008.03.008","article-title":"Life-threatening serotonin toxicity due to a citalopram-fluconazole drug interaction: case reports and discussion","volume":"30","author":"Levin","year":"2008","journal-title":"Gen Hosp Psychiatry"},{"key":"10.1016\/j.jpainsymman.2019.02.006_bib46","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1097\/01.SMJ.0000084311.35864.D6","article-title":"Selective serotonin reuptake inhibitor-induced rhabdomyolysis associated with irinotecan","volume":"96","author":"Richards","year":"2003","journal-title":"South Med J"},{"key":"10.1016\/j.jpainsymman.2019.02.006_bib47","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.jemermed.2008.01.003","article-title":"Serotonin syndrome precipitated by fentanyl during procedural sedation","volume":"38","author":"Kirschner","year":"2010","journal-title":"J\u00a0Emerg Med"},{"key":"10.1016\/j.jpainsymman.2019.02.006_bib48","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0304-3959(02)00461-X","article-title":"High dose methadone and ventricular arrhythmias: a report of three cases","volume":"103","author":"Walker","year":"2003","journal-title":"Pain"},{"key":"10.1016\/j.jpainsymman.2019.02.006_bib49","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1097\/01.jcp.0000239793.29449.75","article-title":"Serotonin syndrome precipitated by linezolid in a medically ill patient on duloxetine","volume":"26","author":"Strouse","year":"2006","journal-title":"J\u00a0Clin Psychopharmacol"},{"key":"10.1016\/j.jpainsymman.2019.02.006_bib50","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1176\/appi.psy.46.6.565","article-title":"Antidepressant and statin interactions: a review and case report of simvastatin and nefazodone-induced rhabdomyolysis and transaminitis","volume":"46","author":"Karnik","year":"2005","journal-title":"Psychosomatics"},{"key":"10.1016\/j.jpainsymman.2019.02.006_bib51","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1089\/jpm.2004.7.861","article-title":"Neuroleptic malignant syndrome after haloperidol and fentanyl infusion in a patient with cancer with severe mineral imbalance","volume":"7","author":"Morita","year":"2004","journal-title":"J\u00a0Palliat Med"},{"key":"10.1016\/j.jpainsymman.2019.02.006_bib52","first-page":"367","article-title":"A\u00a0probable drug-to-drug interaction between voriconazole and haloperidol in a CYP2C19 poor metabolizing patient. [corrected]","volume":"23","author":"Motta","year":"2015","journal-title":"Infez Med Riv Period Eziologia Epidemiol Diagn Clin E Ter Delle Patol Infett"},{"key":"10.1016\/j.jpainsymman.2019.02.006_bib53","first-page":"89","article-title":"Erratum: a probable drug-to-drug interaction between voriconazole and haloperidol in a slow metabolizer of CYP2C19 patient","volume":"24","author":"Motta","year":"2016","journal-title":"Infez Med Riv Period Eziologia Epidemiol Diagn Clin E Ter Delle Patol Infett"},{"key":"10.1016\/j.jpainsymman.2019.02.006_bib54","first-page":"470","article-title":"Drug interaction between idelalisib and diazepam resulting in altered mental status and respiratory failure","volume":"23","author":"Bossaer","year":"2017","journal-title":"J\u00a0Oncol Pharm Pract Off Publ Int Soc Oncol Pharm Pract"},{"key":"10.1016\/j.jpainsymman.2019.02.006_bib55","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1056\/NEJMoa041888","article-title":"Codeine intoxication associated with ultrarapid CYP2D6 metabolism","volume":"351","author":"Gasche","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jpainsymman.2019.02.006_bib56","first-page":"60","article-title":"Cimetidine potentiation of narcotic action","volume":"17","author":"Sorkin","year":"1983","journal-title":"Drug Intell Clin Pharm"},{"key":"10.1016\/j.jpainsymman.2019.02.006_bib57","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1160\/TH12-03-0156","article-title":"Spontaneous gross haematuria during dabigatran therapy for secondary stroke prevention","volume":"108","author":"St\u00f6llberger","year":"2012","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jpainsymman.2019.02.006_bib59","first-page":"1113","article-title":"Reducing potentially inappropriate medications in palliative cancer patients: evidence to support deprescribing approaches","volume":"22","author":"Lindsay","year":"2014","journal-title":"Support Care Cancer Off J Multinatl Assoc Support Care Cancer"},{"key":"10.1016\/j.jpainsymman.2019.02.006_bib60","first-page":"745","article-title":"Futile medication use in terminally ill cancer patients","volume":"17","author":"Riechelmann","year":"2009","journal-title":"Support Care Cancer Off J Multinatl Assoc Support Care Cancer"}],"container-title":["Journal of Pain and Symptom Management"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0885392419300570?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0885392419300570?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:25:10Z","timestamp":1760131510000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0885392419300570"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":58,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S0885392419300570"],"URL":"https:\/\/doi.org\/10.1016\/j.jpainsymman.2019.02.006","relation":{},"ISSN":["0885-3924"],"issn-type":[{"value":"0885-3924","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinically Significant Drug-Drug Interactions Involving Medications Used for Symptom Control in Patients With Advanced Malignant Disease: A Systematic Review","name":"articletitle","label":"Article Title"},{"value":"Journal of Pain and Symptom Management","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpainsymman.2019.02.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}